Ignite Creation Date:
2024-05-05 @ 10:00 AM
Last Modification Date:
2024-10-26 @ 9:05 AM
Study NCT ID:
NCT00006361
Status:
COMPLETED
Last Update Posted:
2009-12-04
First Post:
2000-10-04
Brief Title:
SU5416 in Treating Patients With Advanced or Recurrent Cancer of the Head and Neck
Sponsor:
Memorial Sloan Kettering Cancer Center
Organization:
National Cancer Institute NCI
Study Overview
Official Title:
A Phase II Trial of SU5416 NSC 696819 in Patients With Advanced or Recurrent Squamous Cell Carcinoma of the Head and Neck
Status:
COMPLETED
Status Verified Date:
2002-12
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
RATIONALE SU5416 may stop the growth of cancer cells by stopping blood flow to the tumor
PURPOSE Phase II trial to study the effectiveness of SU5416 in treating patients who have advanced or recurrent cancer of the head and neck
PURPOSE Phase II trial to study the effectiveness of SU5416 in treating patients who have advanced or recurrent cancer of the head and neck
Detailed Description:
OBJECTIVES
Determine the effect of SU5416 on survival and tumor response in patients with advanced or recurrent squamous cell carcinoma of the head and neck
Determine the safety and toxicity of SU5416 in these patients
OUTLINE Patients receive SU5416 IV over 1 hour twice weekly Treatment continues in the absence of disease progression or unacceptable toxicity
Patients are followed for 1 year
PROJECTED ACCRUAL A total of 35 patients will be accrued for this study within 14 years
Determine the effect of SU5416 on survival and tumor response in patients with advanced or recurrent squamous cell carcinoma of the head and neck
Determine the safety and toxicity of SU5416 in these patients
OUTLINE Patients receive SU5416 IV over 1 hour twice weekly Treatment continues in the absence of disease progression or unacceptable toxicity
Patients are followed for 1 year
PROJECTED ACCRUAL A total of 35 patients will be accrued for this study within 14 years
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None
Secondary IDs
| Secondary ID | Type | Domain | Link |
|---|---|---|---|
| NCI-79 | None | None | None |
| MSKCC-00049 | None | None | None |